Rebecca Hurst Davis1, Elizabeth A Miller2, Ren Zhe Zhang2, Kathryn J Swoboda3. 1. Pediatric Motor Disorders Research Program, Department of Neurology, University of Utah, Salt Lake City, UT; Division of Nutrition, University of Utah, Salt Lake City, UT. Electronic address: becky.hurst@utah.edu. 2. Pediatric Motor Disorders Research Program, Department of Neurology, University of Utah, Salt Lake City, UT. 3. Pediatric Motor Disorders Research Program, Department of Neurology, University of Utah, Salt Lake City, UT. Electronic address: kswoboda@mgh.harvard.edu.
Abstract
OBJECTIVE: To examine the impact of fasting and glucose tolerance on selected metabolic variables in children with spinal muscular atrophy (SMA) type II in a well state, secondary to reports of glucose regulation abnormalities in SMA. STUDY DESIGN: In this prospective pilot study, 6 children aged 7-11 years with SMA type II participated in an oral glucose tolerance test and a supervised medical fast during 2 overnight visits at the University of Utah. At baseline, a dual-energy x-ray absorptiometry scan was performed to determine body composition. Laboratory test results were obtained at baseline and in response to the respective interventions. Data analysis was descriptive. Prefasting and postfasting data were evaluated using the Wilcoxon signed-rank test. RESULTS: Based on the dual-energy x-ray absorptiometry scan, all 6 children were variably obese at baseline. All 6 exhibited hyperinsulinemia, and 3 of 6 met formal American Diabetes Association criteria for impaired glucose tolerance. According to homeostatic insulin resistance calculations, 5 of the 6 participants were insulin-resistant. All 6 participants tolerated a monitored fast for 20 hours without hypoglycemia (blood glucose <54 mg/dL). Free fatty acid levels increased significantly from prefasting to postfasting, whereas levels of several plasma amino acids decreased significantly during fasting. CONCLUSION: Children with SMA type II defined as obese using objective variables are at increased risk for impaired glucose tolerance regardless of whether or not they visually appear obese. Further studies are needed to determine the prevalence of impaired glucose tolerance and tolerance for fasting within the broader heterogeneous SMA population and to develop appropriate guidelines for intervention.
OBJECTIVE: To examine the impact of fasting and glucose tolerance on selected metabolic variables in children with spinal muscular atrophy (SMA) type II in a well state, secondary to reports of glucose regulation abnormalities in SMA. STUDY DESIGN: In this prospective pilot study, 6 children aged 7-11 years with SMA type II participated in an oral glucose tolerance test and a supervised medical fast during 2 overnight visits at the University of Utah. At baseline, a dual-energy x-ray absorptiometry scan was performed to determine body composition. Laboratory test results were obtained at baseline and in response to the respective interventions. Data analysis was descriptive. Prefasting and postfasting data were evaluated using the Wilcoxon signed-rank test. RESULTS: Based on the dual-energy x-ray absorptiometry scan, all 6 children were variably obese at baseline. All 6 exhibited hyperinsulinemia, and 3 of 6 met formal American Diabetes Association criteria for impaired glucose tolerance. According to homeostatic insulin resistance calculations, 5 of the 6 participants were insulin-resistant. All 6 participants tolerated a monitored fast for 20 hours without hypoglycemia (blood glucose <54 mg/dL). Free fatty acid levels increased significantly from prefasting to postfasting, whereas levels of several plasma amino acids decreased significantly during fasting. CONCLUSION:Children with SMA type II defined as obese using objective variables are at increased risk for impaired glucose tolerance regardless of whether or not they visually appear obese. Further studies are needed to determine the prevalence of impaired glucose tolerance and tolerance for fasting within the broader heterogeneous SMA population and to develop appropriate guidelines for intervention.
Authors: Aoife Reilly; Marc-Olivier Deguise; Ariane Beauvais; Rebecca Yaworski; Simon Thebault; Daniel R Tessier; Vincent Tabard-Cossa; Niko Hensel; Bernard L Schneider; Rashmi Kothary Journal: Gene Ther Date: 2022-04-25 Impact factor: 4.184
Authors: Suzan M Hammond; Gareth Hazell; Fazel Shabanpoor; Amer F Saleh; Melissa Bowerman; James N Sleigh; Katharina E Meijboom; Haiyan Zhou; Francesco Muntoni; Kevin Talbot; Michael J Gait; Matthew J A Wood Journal: Proc Natl Acad Sci U S A Date: 2016-09-12 Impact factor: 11.205
Authors: Lisa M Walter; Christiane E Koch; Corinne A Betts; Nina Ahlskog; Katharina E Meijboom; Tirsa L E van Westering; Gareth Hazell; Amarjit Bhomra; Peter Claus; Henrik Oster; Matthew J A Wood; Melissa Bowerman Journal: Hum Mol Genet Date: 2018-10-15 Impact factor: 6.150
Authors: Marc-Olivier Deguise; Giovanni Baranello; Chiara Mastella; Ariane Beauvais; Jean Michaud; Alessandro Leone; Ramona De Amicis; Alberto Battezzati; Christopher Dunham; Kathryn Selby; Jodi Warman Chardon; Hugh J McMillan; Yu-Ting Huang; Natalie L Courtney; Alannah J Mole; Sabrina Kubinski; Peter Claus; Lyndsay M Murray; Melissa Bowerman; Thomas H Gillingwater; Simona Bertoli; Simon H Parson; Rashmi Kothary Journal: Ann Clin Transl Neurol Date: 2019-07-26 Impact factor: 4.511
Authors: Wiebke A Rehorst; Maximilian P Thelen; Hendrik Nolte; Clara Türk; Sebahattin Cirak; Jonathan M Peterson; G William Wong; Brunhilde Wirth; Marcus Krüger; Dominic Winter; Min Jeong Kye Journal: Acta Neuropathol Commun Date: 2019-10-15 Impact factor: 7.801